Rekombinanter PCSK9 (Alirocumab Biosimilar) Antikörper
Research Grade
Reaktivität: Human
ELISA
Wirt: Mammalian Cells
Monoclonal
unconjugated
Recombinant Antibody
-
- Target
- PCSK9 (Alirocumab Biosimilar)
- Antikörpertyp
- Recombinant Antibody
- Reaktivität
- Human
- Wirt
-
Mammalian Cells
- Expressionssystem
- Mammalian cells
- Klonalität
- Monoklonal
- Applikation
- ELISA
- Verwendungszweck
- Alirocumab Biosimilar - Anti-PCSK9 mAb
- Produktmerkmale
- Antibody Type: IgG1-kappa
- Aufreinigung
- Recombinant antibody expressed in mammalien cells and purified.
- Güteklasse
- Research Grade
- Isotyp
- IgG1 kappa
-
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Buffer
- PBS pH 7.5
- Lagerung
- -80 °C
- Informationen zur Lagerung
- store at -80°C
-
- Target
- PCSK9 (Alirocumab Biosimilar)
- Substanzklasse
- Biosimilar
- Hintergrund
-
REGN727,SAR-236553
Alirocumab is a human IgG2 monoclonal antibody that binds to and prevents the binding of the proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that binds to LDL receptors for degradation, thus reducing the liver’s activity of removal of LDL-cholesterol (LDL-C) from the blood. It is used in the treatment of hyperlipidemia. - CAS-Nummer
- 1245916-14-6
-
Sie sind hier:
